United States Patent 8,877,230: Testosterone Nasal Gel Claims, Exclusivity and Patent Landscape

US Patent No. 8,877,230 protects methods of treating testosterone deficiency with a testosterone nasal gel or oleogel. Its central limitations are intranasal administration into both nostrils, a testosterone concentration of approximately 0.5% to 6% by weight, and maintenance of testosterone above the patient’s baseline for at least six hours.

The claims are method-of-treatment claims rather than claims directed solely to a composition, device, or manufacturing process. The patent is closely associated with testosterone nasal gel products such as Natesto, marketed by Acerus Pharmaceuticals and originally developed by Trimel Pharmaceuticals.

What does US Patent 8,877,230 protect?

The independent claims protect two related treatment platforms:

Claim group	Protected subject matter	Principal limitations
Claim 1	Testosterone nasal gel treatment	Gel applied to nasal mucosa in each nostril; 0.5%-6% testosterone; elevated serum testosterone; level above baseline for at least six hours
Claims 2-12	Dependent gel-treatment claims	Multi-dose device, controlled release, sustained serum levels, brain delivery, one administration per nostril, physiologic unbound testosterone rhythm, and narrower concentration ranges
Claim 13	Testosterone oleogel treatment	Oleogel applied to nasal mucosa in each nostril; 0.5%-6% testosterone; controlled release; sustained serum levels above baseline for at least six hours
Claims 14-23	Dependent oleogel-treatment claims	Multi-dose device, systemic or brain delivery, one application per nostril, sustained serum levels, and narrower concentration ranges

The broadest practical coverage is found in Claims 1 and 13. A competing product would face the greatest literal infringement exposure if it uses:

Testosterone in a gel or oleogel.
Intranasal administration to both nostrils.
A concentration between approximately 0.5% and 6% by weight.
A resulting serum testosterone level above the patient’s baseline for at least six hours.

The claims require an outcome, not merely a formulation. A product that contains testosterone at a covered concentration but does not achieve the claimed serum-level duration may have a noninfringement position, although actual infringement analysis would depend on clinical evidence, labeling, instructions for use, and the construction of the claim terms.

How should Claim 1 be construed?

Claim 1 contains several limitations that collectively narrow its scope.

Patient and therapeutic indication

The patient must be in need of testosterone replacement therapy. The claim therefore targets treatment of testosterone deficiency or hypogonadal conditions rather than general androgen administration.

The indication limitation may be important in a branded-versus-generic dispute. A generic label that directs treatment only for an FDA-approved testosterone-replacement indication may still create induced-infringement risk if the labeled use practices the patented method.

Nasal route and bilateral administration

The testosterone gel must be administered to the nasal mucosa of each nostril. A formulation administered orally, transdermally, intramuscularly, subcutaneously, or into only one nostril would not satisfy the literal bilateral-administration limitation.

The claims do not expressly require a particular pump, applicator geometry, dosage volume, excipient, or nasal residence time. Claims 2 and 14 add a multi-dose delivery device, but the independent claims do not require that device.

Testosterone concentration

The independent claims recite approximately 0.5% to approximately 6% testosterone by weight. The dependent claims create narrower concentration positions:

Claim	Concentration
Claim 1 or 13	About 0.5%-6%
Claims 10 and 21	About 2%-4%
Claims 11 and 22	About 0.5%-2%
Claims 12 and 23	About 2%

The concentration limitations are formulation-based and do not necessarily correspond to the delivered dose. A product can fall within the claimed percentage range while using a different pump volume, dose per actuation, or dosing frequency.

The term “about” introduces ordinary patent-construction questions concerning analytical precision, formulation variability, batch tolerances, and whether the claimed range is assessed by nominal formulation composition or measured concentration.

Serum testosterone outcome

Claim 1 requires an elevated testosterone serum level after nasal administration and requires that the achieved level remain above the patient’s baseline for at least six hours. Claims 8 and 9 narrow this duration to at least about eight and about ten hours.

These are performance limitations. They may be assessed through pharmacokinetic studies, including baseline-adjusted serum testosterone measurements over time. The claim does not specify a fixed target serum concentration, a required peak concentration, a particular sampling schedule, or a required testosterone exposure area under the curve.

What do the dependent claims add?

Claims 2 through 12 and 14 through 23 divide the technical scope into delivery, pharmacokinetic, tissue-distribution, and concentration limitations.

Multi-dose nasal device

Claims 2 and 14 require a device capable of dispensing multiple individual doses to the nasal mucosa of each nostril. This limitation favors a metered pump or equivalent dispenser rather than a single-use container.

Claim 14 contains the phrase “each nostril multiple,” which appears grammatically defective. The likely substantive concept is a device capable of dispensing multiple individual doses to each nostril. The enforceable meaning would depend on the issued patent text, prosecution history, and claim-construction record.

Controlled release and sustained serum levels

Claims 3, 4, 15, and 22 address controlled release and sustained testosterone levels. These claims are narrower than the independent claims because they require a controlled-release or sustained-release characteristic in addition to the core nasal-treatment limitations.

“Controlled release” may involve the formulation’s release behavior after application. “Sustained serum levels” focuses on the patient’s pharmacokinetic result. The two concepts overlap but are not identical.

Brain delivery

Claims 5 and 16 recite controlled release of testosterone into the brain after nasal application. These claims potentially cover a nose-to-brain delivery objective, but they introduce proof issues concerning the meaning of “into the brain,” the required level of testosterone exposure, and the evidence needed to establish that result.

Claims 5 and 16 are narrower than the systemic-treatment claims. A product can satisfy the systemic-release limitations without satisfying a brain-delivery limitation.

One application per nostril

Claims 6 and 17 require achievement of the serum level after one administration or application per nostril. This limitation may distinguish regimens requiring repeated applications to each nostril to achieve the claimed level.

Physiologic daily rhythm

Claims 7 and 18 require unbound testosterone levels similar to the physiologic daily rhythm of testosterone release. This limitation concerns free or unbound testosterone rather than total testosterone alone.

The phrase “similar to” is fact-intensive. Relevant evidence could include diurnal concentration curves, peak-to-trough variation, timing of administration, and comparison with endogenous testosterone patterns.

What formulations are protected by US 8,877,230?

The patent covers testosterone in a nasal gel and testosterone in a nasal oleogel within the recited concentration ranges. The claims do not limit the formulation to a single excipient system.

An oleogel generally uses an oil-based or lipid-containing gel structure. The independent oleogel claims therefore create a separate claim category that may reach formulations outside a conventional aqueous or hydroalcoholic gel architecture.

The patent does not, based on the supplied claims, require:

A particular gelling polymer.
A specific oil or emollient.
A defined particle size.
A particular preservative.
A specified viscosity.
A specific pump volume.
A particular testosterone ester.
A specific dosing frequency.

Those omissions provide potential design-around opportunities, but a formulation change alone may not avoid the method claims if the resulting product remains a testosterone gel or oleogel, is administered to both nostrils, falls within the concentration range, and produces the claimed pharmacokinetic outcome.

How does the patent relate to Natesto?

Natesto is an FDA-approved testosterone nasal gel for testosterone replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone. The FDA-approved product uses a metered nasal pump and is administered into each nostril. The product contains 4.5 mg of testosterone per actuation, with dosing administered multiple times daily according to the approved labeling (U.S. Food and Drug Administration, 2014).

That product profile aligns closely with the principal limitations of US 8,877,230:

Patent limitation	Natesto product profile
Testosterone nasal gel	Yes
Administration to each nostril	Yes
Multi-dose delivery device	Yes
Testosterone replacement therapy	Yes
Repeated intranasal dosing	Yes
Concentration within the claimed range	Product labeling and formulation data are relevant
Serum testosterone above baseline	Clinical pharmacology data are relevant
Six-hour duration	Requires assessment against clinical pharmacokinetic evidence

A product’s commercial association with the patent does not by itself establish infringement. The relevant inquiry is whether the product’s labeled or actual method of use practices each asserted claim limitation.

What is the Orange Book status of US 8,877,230?

US 8,877,230 has been associated with the FDA-approved testosterone nasal gel product Natesto in public drug-patent and Orange Book records. Orange Book listing establishes that the patent was submitted by the NDA holder for the approved drug and dosage form. It does not establish that every claim is valid or infringed.

The key regulatory consequences are:

An ANDA applicant must address the listed patent.
The applicant may file a Paragraph III certification or Paragraph IV certification.
A Paragraph IV notice can trigger patent litigation under the Hatch-Waxman framework.
A timely infringement action can impose a statutory stay of FDA approval, subject to the statute’s requirements and limitations.
Approval timing depends on the patent certification, litigation, exclusivity, and any settlement arrangement.

The Orange Book should be checked by NDA number and current product entry because listed patents, expiration dates, and patent-use codes can change through FDA updates (U.S. Food and Drug Administration, 2024).

When does US Patent 8,877,230 lose exclusivity?

Public patent records associate US 8,877,230 with a June 2029 expiration date. The relevant Orange Book expiration date should control pharmaceutical launch analysis because it reflects the date reported by FDA for the listed patent.

Milestone	Date or status
Priority period	2009 priority claimed in the patent family records
Patent issued	November 4, 2014
Commercial product association	Natesto testosterone nasal gel
Listed patent expiration	June 2029, subject to the current Orange Book record
Regulatory exclusivity	Distinct from patent exclusivity and must be assessed separately
Generic entry	Earliest entry depends on Paragraph IV litigation, settlement, and regulatory approval

Patent expiration does not automatically mean immediate generic launch. A generic applicant may have approval delayed by other listed patents, pediatric exclusivity, litigation settlements, or regulatory deficiencies.

Which companies are challenging the patent?

The public record supplied here does not establish a particular successful Paragraph IV challenge, final judgment, or enforceable settlement involving US 8,877,230. A complete challenge assessment requires review of current FDA Orange Book records, ANDA litigation dockets, and PACER or district-court filings.

The principal likely challenger category is a generic-drug manufacturer seeking approval of a testosterone nasal gel under an ANDA. A biosimilar pathway is not relevant because testosterone is a small-molecule active pharmaceutical ingredient, not a biologic.

A Paragraph IV challenge could attack:

Anticipation by earlier intranasal testosterone formulations.
Obviousness based on nasal testosterone delivery, gel systems, and pharmacokinetic references.
Written description support for the broad concentration and duration ranges.
Enablement of six-, eight-, and ten-hour serum-level outcomes across the full claim scope.
Definiteness of terms such as “about,” “sustained,” “similar to,” and “controlled release.”
Infringement based on whether the accused product achieves the required serum profile.

How strong is the patent estate?

US 8,877,230 has commercially meaningful claim coverage because it combines formulation, route, dosing site, and pharmacokinetic outcome limitations. The bilateral nasal-administration requirement and serum-duration requirement can narrow prior-art exposure, while the 0.5%-6% concentration range is comparatively broad.

Strength factor	Assessment
Product correlation	Strong if the approved product practices each limitation
Formulation breadth	Moderate to broad
Route limitation	Narrower than general testosterone-delivery claims
Pharmacokinetic limitation	Useful for product linkage but creates proof burdens
Concentration range	Broad, with narrower dependent fallback claims
Device coverage	Dependent claims provide metered-device coverage
Brain-delivery claims	Narrow and technically difficult to prove
Generic design-around risk	Moderate
Biosimilar exposure	Not applicable
Manufacturing protection	Limited in the supplied claims

The patent’s principal vulnerability is that several limitations are functional or result-oriented. Such limitations can improve product specificity but may be challenged if the specification does not adequately support the full claimed range or if the outcome varies materially with patient characteristics, dosing conditions, or measurement methodology.

What generic launch risks exist?

A generic manufacturer has several possible strategies:

File a Paragraph III certification and wait for patent expiration.
File a Paragraph IV certification challenging validity or alleging noninfringement.
Develop a product outside the claimed testosterone concentration range.
Use a single-nostril or nonbilateral administration strategy, if commercially and medically viable.
Use a formulation that does not produce serum testosterone above baseline for six hours.
Pursue a different nasal dosage form, such as a spray, solution, powder, or suspension.
Seek a label that omits a patented use, subject to induced-infringement and skinny-label risks.

The most practical design-around would likely require a material change in route, dosage form, concentration, dosing regimen, or pharmacokinetic profile. Simply changing excipients may not be sufficient.

What geographic coverage does the patent provide?

US 8,877,230 provides rights in the United States only. Corresponding foreign applications may protect related testosterone nasal-gel technology in other jurisdictions, but foreign rights must be assessed separately by patent family and national phase.

The US patent does not itself block:

Manufacturing outside the United States for purely foreign commercialization.
Foreign sales where no corresponding local patent exists.
Noninfringing research activity within the scope of applicable statutory exceptions.

Importing a product into the United States, selling it in the United States, or inducing the patented treatment method can create separate infringement theories.

What manufacturing and intellectual-property barriers remain?

The supplied claims do not directly claim a manufacturing process. They protect use of the finished gel or oleogel in a treatment method. A competitor may therefore avoid direct process-claim exposure while still facing method-of-use risk.

The main technical barriers are:

Achieving adequate nasal absorption.
Maintaining formulation stability.
Controlling dose uniformity across repeated pump actuations.
Limiting leakage, swallowing, and mucociliary clearance.
Producing sustained serum testosterone without excessive peak exposure.
Demonstrating consistent delivery across patients.
Preserving device performance through shelf life.

These technical constraints can create commercial barriers even where a competitor avoids literal infringement.

Key Takeaways

US 8,877,230 protects intranasal testosterone replacement using a gel or oleogel.
The core claim requires administration to each nostril, testosterone at about 0.5%-6% by weight, and serum testosterone above baseline for at least six hours.
Dependent claims cover narrower concentration ranges, multi-dose devices, controlled release, sustained serum levels, one application per nostril, physiologic free-testosterone rhythms, and brain delivery.
The claim architecture closely corresponds to the commercial profile of Natesto.
The patent is publicly associated with a June 2029 expiration date.
The patent is a small-molecule drug patent, so biosimilar risk is not applicable.
Generic exposure will turn on Orange Book listings, Paragraph IV certifications, claim construction, pharmacokinetic evidence, and any settlement terms.
The strongest design-around paths involve changing the route, dosage form, concentration, bilateral-administration pattern, or serum-duration profile.

FAQs

Is testosterone nasal gel covered by US Patent 8,877,230?

Yes, when the product and use satisfy the claim limitations, including bilateral nasal administration, a testosterone concentration of approximately 0.5%-6%, and maintenance of serum testosterone above baseline for at least six hours.

Does the patent cover testosterone nasal spray?

Not automatically. A spray may infringe if it delivers a testosterone gel or oleogel and practices every claim limitation. A liquid spray, powder, or other dosage form may avoid the claims depending on its composition and method of use.

Does US 8,877,230 cover one-nostril administration?

The independent claims require administration to the nasal mucosa of each nostril. A one-nostril regimen has a potential literal noninfringement position, although doctrine-of-equivalents issues may remain fact-dependent.

Is Natesto protected by formulation patents beyond US 8,877,230?

Natesto may be associated with additional patent-family or regulatory protections. Current Orange Book entries and the complete US and foreign patent family must be reviewed to identify all active product-specific rights.

Can a generic launch before June 2029?

Potentially, but only through an applicable patent strategy, such as a successful Paragraph IV challenge, a settlement permitting earlier entry, or a noninfringing product and regulatory pathway. Patent expiration alone is not the only factor governing launch timing.

References

Acerus Pharmaceuticals Corporation. (2018). Natesto (testosterone) nasal gel prescribing information. U.S. Food and Drug Administration labeling archive.
Google Patents. (2014). US8877230B2: Testosterone nasal gel. U.S. Patent and Trademark Office patent publication record. https://patents.google.com/patent/US8877230B2
U.S. Food and Drug Administration. (2014). FDA approves Natesto testosterone nasal gel. FDA drug approval records.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,877,230: Testosterone nasal gel. Washington, DC: U.S. Department of Commerce.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	03025769	Nov 11, 2003

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	047722	⤷ Start Trial
Austria	319426	⤷ Start Trial
Australia	2004286781	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,877,230

Summary for Patent: 8,877,230